AI, automation, and machine learning all have the potential to impact the customer experience – for both patients and HCPs – ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

At the Axtria Ignite 2025 conference, web editor Nicole Raleigh spoke with Mark Montgomery, VP & international head, ...

The algorithm, developed by AI specialist Lunit, was retrospectively tested in conjunction with an advanced 3D mammography ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

There was consternation among the research community yesterday after it emerged that the White House's Office of Management ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three ...

Roberts has been at the helm of NICE for four years, taking over in February 2022 after the departure of Prof Gillian Leng, who decided to step down after the death of her husband, former Public ...

In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

Diagnostics provide the insight, but only a connected pathway turns that insight into real-world impact. That means ensuring ...